Literature DB >> 1405355

Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity.

A Fogo1, S E Hellings, T Inagami, V Kon.   

Abstract

Endothelin (Et) has been implicated in cyclosporine A (CsA) nephrotoxicity. We have previously shown that CsA treatment in rats results in up-regulation of Et receptors specifically within the kidney. The role of Et in vivo CsA nephrotoxicity was therefore studied further with a new competitive antagonist, BQ-123, specific for Et(A) receptors (EtRA). Systemic administration of CsA in Munich-Wistar rats resulted in marked glomerular hypoperfusion and hypofiltration, with RPF in left and right kidneys falling by some 40% to 1.60 +/- 0.25 and 1.73 +/- 0.38 ml/min and GFR decreasing by some 20% to 0.61 +/- 0.05 and 0.67 +/- 0.11 ml/min, respectively. Selective infusion of EtRA into the left renal artery following systemic CsA treatment had no effect on this hemodynamic pattern (RPF 1.58 +/- 0.29 and 1.92 +/- 0.34 ml/min and GFR 0.60 +/- 0.09 and 0.70 +/- 0.08 ml/min in left and right kidneys, respectively, P = NS vs. CsA period). By contrast, intrarenal infusion of EtRA prior to systemic administration of CsA resulted in a strikingly different pattern of renal hemodynamics. Thus, EtRA pretreatment in the left kidney protected against glomerular dysfunction following CsA: RPF was maintained, 3.23 +/- 0.28 ml/min versus 2.96 +/- 0.31 (P = NS EtRA vs. EtRA + CsA), as was the GFR, 1.04 +/- 0.16 ml/min versus 1.12 +/- 0.09 (P = NS). However, the contralateral right kidneys of these rats, not pretreated with EtRA, showed no protective effect: RPF decreased from 3.15 +/- 0.34 ml/min to 2.39 +/- 0.19 and GFR from 1.04 +/- 0.10 ml/min to 0.85 +/- 0.07 (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405355     DOI: 10.1038/ki.1992.346

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 2.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 3.  Hypertension after renal transplantation.

Authors:  V Schwenger; M Zeier; E Ritz
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

4.  Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

Authors:  Shirin Bruderer; Päivi Aänismaa; Marie-Claude Homery; Stephanie Häusler; Kyle Landskroner; Patricia N Sidharta; Alexander Treiber; Jasper Dingemanse
Journal:  AAPS J       Date:  2011-12-22       Impact factor: 4.009

Review 5.  Role of endothelin in hypertension.

Authors:  B K Krämer; M Ackermann; S M Kohler; G A Riegger
Journal:  Clin Investig       Date:  1994-01

Review 6.  Endothelin: potential role in development and disease.

Authors:  V Kon; A Fogo
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

Review 7.  The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction.

Authors:  M Jerkić; S Vojvodić; J M López-Novoa
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

8.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Divergent expression of EtA and EtB receptors in response to cyclosporine in mesangial cells.

Authors:  M Takeda; S Iwasaki; S E Hellings; H Yoshida; T Homma; V Kon
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

10.  Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.

Authors:  J J Maguire; R E Kuc; G O'Reilly; A P Davenport
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.